InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation
InterCure (Nasdaq: INCR) entered a definitive Share Purchase Agreement and Collaboration Agreement with Cannasoul on Nov 3, 2025, taking a 28% ownership stake on a fully diluted basis and an exclusive path to 51% within two years.
The Collaboration Agreement formalizes joint research, development, and commercialization of evidence-based cannabis therapeutics and anticipates Prof. Dedi Meiri joining as Chair of an InterCure Scientific Advisory Board to accelerate R&D integration.
The transaction is subject to customary closing conditions and regulatory approvals; the release notes potential U.S. market opportunities tied to reported federal rescheduling discussions.
InterCure (Nasdaq: INCR) ha stipulato un accordo definitivo di acquisto di azioni e un Accordo di Collaborazione con Cannasoul il 3 novembre 2025, acquisendo una partecipazione del 28% su base totalmente diluita e una strada esclusiva al 51% entro due anni.
L'Accordo di Collaborazione formalizza la ricerca congiunta, lo sviluppo e la commercializzazione di terapie a base di cannabis basate su evidenze e prevede l'ingresso del Prof. Dedi Meiri come Presidente di un InterCure Scientific Advisory Board per accelerare l'integrazione della R&S.
La transazione è soggetta a condizioni di chiusura standard e approvazioni normative; il comunicato segnala potenziali opportunità di mercato statunitense legate a discorsi di riposizionamento federale riportati.
InterCure (Nasdaq: INCR) firmó un Acuerdo Definitivo de Compra de Acciones y un Acuerdo de Colaboración con Cannasoul el 3 de noviembre de 2025, adquiriendo una participación del 28% en base totalmente diluida y un camino exclusivo al 51% dentro de dos años.
El Acuerdo de Colaboración formaliza la investigación, el desarrollo y la comercialización conjuntos de terapéuticas a base de cannabis basadas en evidencia y anticipa la incorporación del Prof. Dedi Meiri como Presidente de un InterCure Scientific Advisory Board para acelerar la integración de I+D.
La transacción está sujeta a las condiciones de cierre habituales y a aprobaciones regulatorias; el comunicado señala oportunidades potenciales en el mercado estadounidense vinculadas a discusiones federales sobre reclassificación reportadas.
InterCure (Nasdaq: INCR)는 Cannasoul과 2025년 11월 3일에 주식매매계약 및 협력계약을 체결하여 완전 희석 기준으로 28% 지분을 확보하고 2년 이내에 51%에 이르는 독점적 경로를 보장합니다.
협력계약은 근거 기반의 대마초 치료제에 대한 공동 연구, 개발 및 상용화를 공식화하며, 연구개발 통합을 가속화하기 위해 인터케어 사무국 과학자 고문위원회의 의장으로 디디 메이리 교수의 합류를 예상합니다.
거래는 관례적인 종결 조건 및 규제 승인의 대상이며, 발표문은 연방 재조정 논의와 관련된 미국 시장 기회 가능성을 지적합니다.
InterCure (Nasdaq: INCR) a conclu le 3 novembre 2025 un accord définitif d'achat d'actions et un accord de collaboration avec Cannasoul, détenant une participation de 28% sur une base entièrement diluée et un chemin exclusif vers 51% dans les deux ans.
L'accord de collaboration formalise la recherche, le développement et la commercialisation conjoints de thérapies à base de cannabis fondées sur des preuves et prévoit l'arrivée du Prof. Dedi Meiri en tant que Président d'un InterCure Scientific Advisory Board afin d'accélérer l'intégration de la R&D.
La transaction est soumise aux conditions de clôture habituelles et aux approbations réglementaires; le communiqué mentionne des opportunités potentielles sur le marché américain liées à des discussions fédérales de reclassification rapportées.
InterCure (Nasdaq: INCR) hat am 3.11.2025 eine endgültige Vereinbarung zum Aktienkauf sowie eine Kooperationsvereinbarung mit Cannasoul unterzeichnet, wodurch eine 28%ige Eigentumsbeteiligung auf voll verwässerter Basis erworben wird und innerhalb von zwei Jahren ein exklusiver Weg zu 51% eröffnet wird.
Die Kooperationsvereinbarung formt die gemeinsame Forschung, Entwicklung und Vermarktung evidenzbasierter Cannabis-Therapeutika und sieht die Aufnahme von Prof. Dedi Meiri als Vorsitzenden eines InterCure Scientific Advisory Board vor, um die F&E-Integration zu beschleunigen.
Die Transaktion unterliegt den üblichen Abschlussbedingungen und behördlichen Genehmigungen; die Mitteilung verweist auf potenzielle Marktchancen in den USA im Zusammenhang mit berichteten bundesweiten Neuordnungsdiskussionen.
InterCure (Nasdaq: INCR) أبرمت اتفاقية نهائية لشراء الأسهم واتفاقية تعاون مع Cannasoul في 3 نوفمبر 2025، لتستحوذ على حصة 28% من الملكية على أساس مخفف بالكامل و< b>مسار حصري إلى 51% خلال عامين.
توّفر اتفاقية التعاون إطاراً للبحث والتطوير والتسويق المشترك للعلاجات القائمة على Cannabis المدعومة بالأدلة وتتوقع انضمام الأستاذ ديدي مييري كرئيس مجلس استشاري علمي لشركة InterCure لتسريع تكامل البحث والتطوير.
الصفقة خاضعة لشروط الإغلاق المعتادة والموافقات التنظيمية؛ تشير النشرة إلى فرص سوق أمريكية محتملة مرتبطة بنقاشات إعادة تصنيف اتحادية أُبلغ عنها.
- 28% ownership stake in Cannasoul on a fully diluted basis
- Exclusive path to increase holdings to 51% within two years
- Formalized R&D and commercialization partnership for cannabis therapeutics
- Expected appointment of Prof. Dedi Meiri as Scientific Advisory Board chair
- Transaction subject to customary closing conditions and regulatory approvals
- Commercial opportunity tied to uncertain U.S. rescheduling discussions
Insights
InterCure buys a strategic stake in Cannasoul and formalizes an R&D collaboration, widening its scientific and commercialization capabilities.
The deal gives InterCure an immediate
This structure pairs InterCure’s pharmaceutical platform with Cannasoul’s analytics and names Prof. Dedi Meiri to the planned Scientific Advisory Board, which should accelerate translational research while centralizing scientific oversight. The transaction remains conditional on customary closing steps and regulatory approvals, so operational benefits depend on closing timing and approvals.
Key risks and dependencies include successful closing, regulatory approvals, and effective operational integration between teams. The press release also references possible U.S. rescheduling from Schedule I to Schedule III, a regulatory development outside the transaction’s explicit terms that could expand U.S. opportunities but is not a disclosed certainty.
Watch for three concrete near-term signals: closing completion and regulatory clearances, appointment details and charter of the Scientific Advisory Board, and early collaborative milestones such as joint study starts or data readouts within the next
Agreements formalize research partnership combining InterCure’s global pharmaceutical platform with Cannasoul’s world-class analytics and scientific innovation
Collaboration comes amidst reports that the Trump administration is exploring cannabis rescheduling, expected to create unprecedented opportunities in the U.S. for international operators like InterCure
NEW YORK & HERZLIYA, Israel , Nov. 03, 2025 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR / TASE: INCR) (“InterCure” or the “Company”) today announced it has entered into a definitive Share Purchase Agreement and a Collaboration Agreement with Cannasoul R&D Ltd. (“Cannasoul”), a globally recognized pioneer in cannabis research and analytics (together, the “Agreements”). The Share Purchase Agreement provides InterCure with a
Notably, the Agreements come as the U.S. cannabis market stands at a historic potential inflection point, with the Trump administration reportedly exploring the rescheduling of cannabis from Schedule I to Schedule III1 - a transformative regulatory shift that could potentially unlock unprecedented opportunities for international cannabis companies such as InterCure.
As part of the Agreements, Prof. Dedi Meiri, Founder of Cannasoul and a globally recognized cannabis researcher at the Technion - Israel Institute of Technology, is expected to be appointed as the Chairperson as of InterCure’s Scientific Advisory Board to be established by the Company’s board of directors. In this role, Prof. Meiri will assist in integrating Cannasoul’s advanced analytics and research capabilities into InterCure’s pharmaceutical platform, strengthening InterCure’s scientific leadership and accelerating the development of next-generation cannabis-based therapeutics.
“The Agreements mark a significant step in InterCure’s global leadership strategy,” said Alex Rabinovitch, Chief Executive Officer of InterCure. “By combining Cannasoul’s established research capabilities with InterCure’s pharmaceutical-grade platform and under the scientific advisory of Prof. Meiri, we plan to accelerate the development of next-generation cannabis therapeutics, expand our international footprint, and drive long-term value for patients and shareholders alike.”
“Cannasoul’s mission has always been to translate cannabis science into meaningful therapies,” said Prof. Dedi Meiri, Founder of Cannasoul. “Through the Agreements and with the establishment of the Scientific Advisory Board, we believe that we now have the structure, resources, and global reach to move discoveries from the lab to patients faster, with the scientific rigor and scale that meaningful innovation demands.”
The transaction remains subject to customary closing conditions and regulatory approvals.
About InterCure
InterCure Ltd. (dba Canndoc) (Nasdaq: INCR) (TASE: INCR) is a leading fast-growing cannabis company operating outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated “seed-to-sale” model to lead the fastest growing cannabis global market outside of North America.
For more information, visit: https://www.intercure.co
About Cannasoul R&D Ltd.
Cannasoul R&D is a leading research and analytics laboratory globally recognized as a pioneer in cannabis science. In collaboration with Prof. Dedi Meiri’s laboratory at the Technion – Israel Institute of Technology, Cannasoul has developed advanced analytical and biological-validation platforms to map cannabis compounds and mechanisms of action. Its research spans preclinical and clinical studies across oncology, neurology, and women’s health.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements may include, but are not limited to, statements regarding the completion and performance of the Agreements with Cannasoul, the collaboration between Cannasoul’s research and analytics platform and InterCure’s pharmaceutical business, the development and commercialization of evidence-based and next-generation cannabis therapeutics, the appointment and activities of Prof. Dedi Meiri as Chairperson of the Scientific Advisory Board, the strengthening of InterCure’s scientific leadership, the acceleration of product development under the Collaboration Agreement, and InterCure’s expectations to expand its international presence and deliver value to patients and shareholders. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy,” and similar expressions, and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Factors that could cause actual results to differ materially include, but are not limited to, the ability of InterCure and Cannasoul to fulfill the conditions of the Agreements and obtain regulatory approvals, the successful execution of R&D and commercialization projects under the Collaboration Agreement, the Company’s success in its global expansion plans, continued growth, expected operations, financial results, business strategy, competitive strengths, and external factors such as the political conditions and the conflict in Israel, the war in Ukraine, and general market conditions. Forward-looking information is based on a number of assumptions and is subject to numerous risks and uncertainties, many of which are beyond InterCure’s control, which could cause actual results and events to differ materially from those disclosed in or implied by such information. Such risks and uncertainties include, but are not limited to, changes in economic, business, and political conditions; changes in applicable laws; regulatory developments and enforcement related to cannabis in Israel, the U.S., and other jurisdictions; changes in public perception of the cannabis industry; and reliance on the expertise and judgment of senior management. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in InterCure’s most recent Annual Report on Form 20-F and in other filings made with the U.S. Securities and Exchange Commission.
Company Contact:
InterCure Ltd.
Amos Cohen, Chief Financial Officer
amos@intercure.co
Investor Relations Contact:
Arx Investor Relations
North American & Israeli Equities Desks
intercure@arxhq.com
1 https://www.cannabisbusinesstimes.com/cannabis-rescheduling/news/15752702/trump-publicly-addresses-cannabis-rescheduling-decision-coming-in-next-few-weeks
FAQ
What did InterCure (INCR) announce on Nov 3, 2025?
How will the InterCure–Cannasoul collaboration affect INCR's research plans?
Who will lead scientific oversight after the InterCure and Cannasoul deal (INCR)?
Does InterCure (INCR) gain control of Cannasoul immediately?
What regulatory risks does the InterCure–Cannasoul agreement (INCR) face?
